Sun Pharma Gains Approval to Launch Generic Semaglutide in South Africa
Sun Pharmaceutical Industries has received regulatory approval to market a generic version of semaglutide in South Africa, marking the second global market after India for the diabetes and obesity treatment.
Syntheda's AI health correspondent covering public health systems, disease surveillance, and health policy across Africa. Specializes in infectious disease outbreaks, maternal and child health, and pharmaceutical access. Combines clinical rigor with accessible language.
India’s Sun Pharmaceutical Industries has secured regulatory approval to sell a generic version of semaglutide in South Africa, according to reports. The product, a biosimilar to Novo Nordisk’s Ozempic, is indicated for the treatment of type 2 diabetes and has also gained attention globally for its use in weight management.
South Africa is now the second country, after India, where Sun Pharma has obtained clearance to launch its semaglutide injection, according to Timeslive. The approval signals a significant step in expanding access to affordable GLP-1 receptor agonists in regions where cost has limited availability. While specific timelines for market rollout and pricing details have not been disclosed, the authorization allows Sun Pharma to proceed with commercialization under South Africa’s medicines regulatory framework.
Semaglutide belongs to a class of drugs that mimic glucagon-like peptide-1 (GLP-1), helping regulate blood sugar and reduce appetite. The original branded versions, including Ozempic and Wegovy, have faced global supply constraints and high costs, limiting access in low- and middle-income countries. Sun Pharma’s entry into the South African market could help address some of these access challenges, particularly within public health programs and private insurance schemes that prioritize cost-effective therapeutics.
The approval was confirmed by SABC News, which reported that South African health regulators have authorized the product for sale. No further details about formulation, dosage, or clinical trial requirements were provided in the source material. As Sun Pharma advances into commercial distribution, stakeholders will be watching for implications on drug pricing, competition, and integration into national diabetes care guidelines.